Plasma metabolome analysis of patients with major depressive disorder
Open Access
- 22 January 2018
- journal article
- research article
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 72 (5) , 349-361
Abstract
Aim: This study sought to characterize the plasma metabolite profiling of patients with major depressive disorder (MDD).Methods: Psychiatric assessments were made with the Structured Clinical Interview for DSM‐IV Axis I Disorders. In the exploratory cohort, plasma metabolite profiles of 34 MDD patients and 31 mentally healthy controls were compared using capillary electrophoresis‐mass spectrometry. Among the candidate metabolites, we focused on a metabolite showing the largest difference. The absolute concentrations were measured in two cohorts from a psychiatric primary care clinic to characterize the accuracy of the metabolite biomarker.Results: Among 23 metabolites significantly lower in the MDD group than in healthy controls, we focused on phosphoethanolamine (PEA) as a candidate. The reduction of PEA levels in MDD was checked in independent clinical sample sets. An ion‐chromatography‐fluorescence detection method was developed to measure plasma PEA levels. In the preliminary cohort, we examined 34 MDD and 43 non‐MDD subjects. The area under the receiver–operator curve (AUC) was 0.92, with sensitivity/specificity greater than 88%, at a cut‐off of 1.46 μM. In the checking cohort, with 10 MDD and 13 non‐MDD subjects, AUC was 0.89, with sensitivity/specificity of 86% and 100%, respectively, at a cut‐off of 1.48 μM. Plasma PEA inversely correlated with MDD severity, depressed mood, loss of interest, and psychomotor retardation.Conclusion: These results suggest that plasma PEA level could be a candidate biomarker of MDD in the clinical setting. Further studies comparing MDD and mentally healthy controls are needed to confirm the utility of PEA as a biomarker for depression.Keywords
Funding Information
- Ministry of Economy (23SH2010)
- Ministry of Education, Culture, Sports, Science and Technology (18390211)
- New Energy and Industrial Technology Development Organization
This publication has 33 references indexed in Scilit:
- Psychomotor Retardation in Depression: A Systematic Review of Diagnostic, Pathophysiologic, and Therapeutic ImplicationsBioMed Research International, 2013
- Data-driven subtypes of major depressive disorder: a systematic reviewBMC Medicine, 2012
- Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication StudyMolecular Psychiatry, 2011
- DNA Methylation Profiles of the Brain-Derived Neurotrophic Factor (BDNF) Gene as a Potent Diagnostic Biomarker in Major DepressionPLOS ONE, 2011
- Functional Biomarkers of Depression: Diagnosis, Treatment, and PathophysiologyNeuropsychopharmacology, 2011
- Immune suppression and immune activation in depressionBrain, Behavior, and Immunity, 2011
- Metabolomic Differences in Heart Failure Patients With and Without Major DepressionJournal of Geriatric Psychiatry and Neurology, 2010
- Inactivity of phosphoethanolamine, an endogenous GABA analog decreased in Alzheimer's disease, at GABA binding sitesLife Sciences, 1995
- Improving depression severity assessment—I. Reliability, internal validity and sensitivity to change of three observer depression scalesJournal of Psychiatric Research, 1988
- Phospholipid Biosynthesis in Myelin: Presence of CTP: Phosphoethanolamine Cytidylyltransferase in Purified Myelin of Rat BrainJournal of Neurochemistry, 1984